top of page
Lake

Drew Hertig MBA, CLP

I enjoy helping life science organizations succeed.

Global business development and corporate strategy experience in the biotechnology and pharmaceutical industries (preclinical/clinical)

​

POSITIONING THE ASSET OR BUSINESS

TECH ASSESSMENT

Step one is performing diligence on the technology or asset: assessing strengths, weaknesses, opportunities and threats. From intellectual property to market size and everything in between.

CUSTOMER DISCOVERY

Next is connecting with potential customers, including all stakeholders along the value chain. Can your product or process perform the job for a margin a customer (or payer) is willing to pay (or reimburse)?

CORPORATE STRATEGY

This includes the business plan to get your product or service to the customer, communicated in a way that stakeholders understand. Are you resourced enough to hit key milestones?

20200627_182756.jpg
HELLO
MY NAME IS

Drew

BUILDING GREAT PRODUCTS AND COMPANIES

OPERATIONS

Mapping out processes to ensure efficient use of capital and other resources by optimizing organizational structure, critical paths items, inputs/outputs, equipment and infrastructure.

BD & MARKETING

Generating awareness and creating interactions ("collisions") that will grow the business. The more channels utilized, the greater the customer access, and the better the partnering options.

LICENSING & SALES

Biotechnology products and services provide significant value to the right customer. Creating the right profile is the key to understanding perceived value to each customer to maximize ROI.

Testimonials

"Drew is a results-oriented collaborator who brings a positive approach to frame and address Business Development (BD) opportunities and challenges. I had the pleasure to collaborate closely with Drew for several months after hiring him as a BD consultant to Viking Therapeutics. Drew astutely leverages a scientific and financial acumen, coupled with hands-on practicality to deliver value added tools, such as a Strategic Target Map (that included H,M,L prioritization), a master Q&A document across clinical and pre-clinical assets, an optimized and granular Partnering Tracker, as well as various market and competitive analysis."

-Amy B., Biopharmaceutical Executive

How Can I Help?

Feel free to reach out to me!

Location:

San Marcos, CA 92078

Contact:

drew@drewhertig.com

Social:

  • linkedin

Thanks for submitting!

Contact
bottom of page